Su Jin HongSoo Heon ParkJeong Seop MoonWoon Geon ShinJae Gyu KimYong Chan LeeDong Ho LeeJae Young JangJae J. KimHang Lak LeeSang Woo LeeYoung HwangboJianming XuBangmao WangZhanxiong XueFei LiuYaozong YuanSomchai LeelakusolvongFrederick DySoonchunhyang University, College of MedicineThe Catholic University of Korea, College of MedicineInje University Paik HospitalHallym University, College of MedicineChung-Ang University, College of MedicineYonsei University College of MedicineSeoul National University Bundang HospitalKyung Hee UniversitySungKyunKwan University, School of MedicineHanYang University, College of MedicineKorea University Medical CenterAnhui Medical UniversityTianjin Medical UniversityWenzhou Medical UniversityTongji UniversityShanghai Jiao Tong UniversityMahidol UniversityUniversity of Santo Tomas Hospital2018-12-112019-03-142018-12-112019-03-142016-11-01Gut and Liver. Vol.10, No.6 (2016)197622832-s2.0-84992602775https://repository.li.mahidol.ac.th/handle/20.500.14594/41079Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.Mahidol UniversityMedicineArticleSCOPUS10.5009/gnl15537